The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury
Best Practice & Research Clinical Endocrinology & Metabolism · 2025-05 · 39 (3) · 102001
DOI: 10.1016/j.beem.2025.102001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Endocrinology & Metabolism, 2025-05. Verfasst von Chiara Mele und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Electronic address: chiara.mele1989@gmail.com. Hauptthemen laut MEDLINE: Brain Injuries, Traumatic, Thyroid Hormones, Hypothalamo-Hypophyseal System, Consciousness Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Traumatic brain injury (TBI) is a leading cause of mortality and long-term disability, with its pathophysiology encompassing both primary mechanical damage and secondary neuroinflammatory, metabolic, and biochemical alterations. These complex mechanisms contribute to the observed heterogeneous clinical outcomes, including neuroendocrine dysfunctions, post-traumatic seizures, and disorders of consciousness (DoC). Thyroid hormones (THs) play essential roles in synaptic plasticity, neurogenesis and neuronal homeostasis, and the hypothalamic-pituitary-thyroid (HPT) axis has recently emerged as a potential acute and chronic modulator of neurological and functional recovery following TBI, thereby hinting at the potential involvement of THs in post-TBI outcomes. While evidence suggests that alterations in the HPT axis may influence susceptibility to seizures, progression of DoC, and rehabilitation outcomes, an increased blood-brain barrier permeability in concert with dysregulated deiodinase activity and expanding oxidative stress have all been proposed as mechanisms linking THs to post-TBI neurological complications. This review aims to summarize current evidence on the potential role of the thyrotropic axis in neurological and rehabilitation outcomes following TBI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Electronic address: chiara.mele1989@gmail.com.
- Department of Endocrinology, UZ Brussel, Laarbeeklaan, Brussels, Belgium.
- Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
- Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Division of Endocrinology and Diabetology, Sant'Andrea Hospital, Azienda Sanitaria Locale (ASL) Vercelli, Vercelli, Italy.
- Department of Health Sciences, University of Piemonte Orientale, Novara, Italy.
Zitieren
APA
Mele, C., De Marchi, L., Pitino, R., Costantini, L., Cavigiolo, B., Caputo, M., Marzullo, P., & Aimaretti, G. (2025). The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury. Best Practice & Research Clinical Endocrinology & Metabolism, 39(3), 102001. https://doi.org/10.1016/j.beem.2025.102001
Vancouver
Mele C, De Marchi L, Pitino R, Costantini L, Cavigiolo B, Caputo M, et al. The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury. Best Practice & Research Clinical Endocrinology & Metabolism. 2025;39(3):102001. doi:10.1016/j.beem.2025.102001
BibTeX
@article{Mele2025,
author = {Mele, Chiara and De Marchi, Lucrezia and Pitino, Rosa and Costantini, Luisa and Cavigiolo, Beatrice and Caputo, Marina and Marzullo, Paolo and Aimaretti, Gianluca},
title = {The interplay between thyrotropic axis, neurological complications, and rehabilitation outcomes in patients with traumatic brain injury},
journal = {Best Practice & Research Clinical Endocrinology & Metabolism},
year = {2025},
volume = {39},
number = {3},
pages = {102001},
doi = {10.1016/j.beem.2025.102001}
}
EUVIMED